Form 4 for MIRA MIRA PHARMACEUTICALS, INC.
Accepted 2025-10-03 00:00:00 ET · period of report 2025-10-01 · accession 0001493152-25-016957 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-03 | 2025-10-01 | MIRA | Aminov Erez | CEO, Dir | A - Grant | — | +2.69M | 3.53M | +318% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-01 | A | A | 2,685,456 | — | 3,530,156 | D | — | — | (F1) Represents 2,685,456 restricted shares of common stock, par value $0.0001 of the Issuer issued as compensation for the Issuer's acquisition of SKNY Pharmaceuticals, Inc. |